Sociedad Americana de Hirudoterapia

New anticoagulant protein from medicinal leech

Basic science / preclinical published in Biochemical and biophysical research communications (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenómica y proteómicaDesarrollo de fármacosFarmacología salivalManuvera V et al. · Biochemical and biophysical research communications, 2024

Abstract

The saliva of the medicinal leech contains various anticoagulants. Some of them, such as hirudin, are well known. However, it is reasonable to believe that not all anticoagulant proteins from medicinal leech saliva have been identified. We previously performed a comprehensive study of the transcriptome, genome, and proteome of leech salivary gland cells, which led to the discovery of several previously unknown hypothetical proteins that may have anticoagulant properties. Subsequently, we obtained a series of recombinant proteins and investigated their impact on coagulation in in vitro assays. We identified a previously undescribed protein that exhibited a high ability to suppress coagulation. The His-tagged recombinant protein was expressed in Escherichia coli and purified using metal chelate chromatography. To determine its activity, commonly used coagulation methods were used: activated partial thromboplastin time, prothrombin time, and thrombin inhibition clotting assay. Clotting and chromogenic assays for factor Xa inhibition were performed to evaluate anti-Xa activity. We used recombinant hirudin as a control anticoagulant protein in all experiments. The new protein showed significantly greater inhibition of coagulation than hirudin at the same molar concentrations in the activated partial thrombin time assay. However, hirudin demonstrated better results in the direct thrombin inhibition test, although the tested protein also exhibited the ability to inhibit thrombin. The chromogenic analysis of factor Xa inhibition revealed no activity, whereas the clotting test for factor Xa showed the opposite result. Thus, a new powerful anticoagulant protein has been discovered in the medicinal leech. This protein is homologous to antistatin, with 28 % identical amino acid residues. The recombinant protein was expressed in E. coli. This protein is capable of directly inhibiting thrombin, and based on indirect evidence, other proteases of the blood coagulation cascade have been identified.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnticoagulantsHirudinsThrombinFactor XaEscherichia coliRecombinant Proteins

Resumen

The saliva of the medicinal leech contains various anticoagulants. Some of them, such as hirudin, are well known.

Por qué esto importa para la hirudoterapia

Este estudio identificó una proteína anticoagulante previamente no descrita en las glándulas salivales de la sanguijuela medicinal mediante análisis transcriptómico, genómico y proteómico, luego la expresó recombinantemente en E. coli y caracterizó su actividad utilizando ensayos de coagulación estándar (aPTT, tiempo de protrombina, inhibición de trombina y pruebas de factor Xa). Este trabajo avanza directamente la caracterización del secretoma salival de la sanguijuela —la base farmacológica de la hirudoterapia— al ampliar el repertorio conocido de proteínas anticoagulantes más allá de hirudin; la nueva proteína, homóloga a antistatin, mostró una mayor supresión de la coagulación que hirudin a concentraciones equimolares en ensayos de aPTT, al mismo tiempo que exhibía actividad inhibidora de la trombina. Todos los hallazgos provienen de ensayos de coagulación in vitro con proteína recombinante purificada, sin que se presenten datos in vivo, en animales o clínicos, y los resultados contradictorios de los ensayos de factor Xa indican que el perfil completo de dianas y el mecanismo de la proteína permanecen sin resolverse completamente.

Citación

New anticoagulant protein from medicinal leech.

Manuvera V et al. · Biochemical and biophysical research communications, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.